These new BDNF-based therapies threaten to disrupt the traditional story around the disease pathophysiology that moves from synaptic failure in AD to poor stress tolerance in MDD; they may also result in more disease-modifying options that allow for an approach to treatment beyond symptoms. This evidence concerns the gene BDNF and Alzheimer disease.